TY - JOUR
T1 - Neutralizing antibodies reveal cryptic vulnerabilities and interdomain crosstalk in the porcine deltacoronavirus spike protein
AU - Du, Wenjuan
AU - Debski-Antoniak, Oliver
AU - Drabek, Dubravka
AU - van Haperen, Rien
AU - van Dortmondt, Melissa
AU - van der Lee, Joline
AU - Drulyte, Ieva
AU - van Kuppeveld, Frank J M
AU - Grosveld, Frank
AU - Hurdiss, Daniel L
AU - Bosch, Berend-Jan
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/6/22
Y1 - 2024/6/22
N2 - Porcine deltacoronavirus (PDCoV) is an emerging enteric pathogen that has recently been detected in humans. Despite this zoonotic concern, the antigenic structure of PDCoV remains unknown. The virus relies on its spike (S) protein for cell entry, making it a prime target for neutralizing antibodies. Here, we generate and characterize a set of neutralizing antibodies targeting the S protein, shedding light on PDCoV S interdomain crosstalk and its vulnerable sites. Among the four identified antibodies, one targets the S1A domain, causing local and long-range conformational changes, resulting in partial exposure of the S1B domain. The other antibodies bind the S1B domain, disrupting binding to aminopeptidase N (APN), the entry receptor for PDCoV. Notably, the epitopes of these S1B-targeting antibodies are concealed in the prefusion S trimer conformation, highlighting the necessity for conformational changes for effective antibody binding. The binding footprint of one S1B binder entirely overlaps with APN-interacting residues and thus targets a highly conserved epitope. These findings provide structural insights into the humoral immune response against the PDCoV S protein, potentially guiding vaccine and therapeutic development for this zoonotic pathogen.
AB - Porcine deltacoronavirus (PDCoV) is an emerging enteric pathogen that has recently been detected in humans. Despite this zoonotic concern, the antigenic structure of PDCoV remains unknown. The virus relies on its spike (S) protein for cell entry, making it a prime target for neutralizing antibodies. Here, we generate and characterize a set of neutralizing antibodies targeting the S protein, shedding light on PDCoV S interdomain crosstalk and its vulnerable sites. Among the four identified antibodies, one targets the S1A domain, causing local and long-range conformational changes, resulting in partial exposure of the S1B domain. The other antibodies bind the S1B domain, disrupting binding to aminopeptidase N (APN), the entry receptor for PDCoV. Notably, the epitopes of these S1B-targeting antibodies are concealed in the prefusion S trimer conformation, highlighting the necessity for conformational changes for effective antibody binding. The binding footprint of one S1B binder entirely overlaps with APN-interacting residues and thus targets a highly conserved epitope. These findings provide structural insights into the humoral immune response against the PDCoV S protein, potentially guiding vaccine and therapeutic development for this zoonotic pathogen.
KW - Animals
KW - Antibodies, Neutralizing/immunology
KW - Antibodies, Viral/immunology
KW - CD13 Antigens/metabolism
KW - Coronavirus Infections/immunology
KW - Deltacoronavirus/immunology
KW - Epitopes/immunology
KW - HEK293 Cells
KW - Humans
KW - Protein Binding
KW - Protein Domains
KW - Spike Glycoprotein, Coronavirus/immunology
KW - Swine
KW - Swine Diseases/virology
UR - http://www.scopus.com/inward/record.url?scp=85196654767&partnerID=8YFLogxK
U2 - 10.1038/s41467-024-49693-0
DO - 10.1038/s41467-024-49693-0
M3 - Article
C2 - 38909062
SN - 2041-1723
VL - 15
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5330
ER -